Tag Idarucizumab

Here is the information contained in the clinical in-service run by Martin Rees (Boehringer Ingelheim) to educate staff prior to allowing the hospital access to Idarucizumab for dabigatran reversal. This agent should be available from early next year. The protocol for it’s…